Harrow Health

Historical price data

Harrow Health has established a distinctive and defensible position in the ophthalmic pharmaceutical sector through its vertically integrated business model, which pairs the recurring, high-margin revenue of its national compounding pharmacy, ImprimisRx, with a strategic portfolio of branded and generic products. Since its founding in 2011, the company has scaled to serve thousands of eyecare providers nationwide and, through seven strategic acquisitions, has assembled a portfolio of 17 branded products and 2 biosimilars. Its strategy centers on leveraging the deep customer relationships and distribution power of its compounding business to accelerate the commercialization of its expanding branded portfolio, targeting a broad range of ocular conditions from dry eye to retinal diseases.

A vertically integrated commercial and formulation platform centered on a market-leading 503B sterile compounding facility (ImprimisRx), which provides customized ophthalmic medications and serves as a low-cost, high-touch distribution channel for its portfolio of branded and generic pharmaceuticals.